文献速递乳腺癌

HER2阳性早期乳腺癌患者对帕妥珠单抗和曲妥珠单抗固定剂量皮下注射组合的偏好:PHranceSCa随机开放标签II期研究

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
PubMed 文献 · Eur J Cancer · 2021-06-16

PHranceSCa研究评估HER2阳性早期乳腺癌患者对PH FDC SC的偏好。85.0%患者偏好SC,主要原因为减少 clinic 时间和给药舒适;SC满意度88.1%高于IV 67.5%;86.9%选择SC继续;安全性与IV相似。

要点

  • 85.0%患者偏好PH FDC SC,主要因减少诊所时间和舒适。
  • 88.1%对SC满意,86.9%选择SC继续治疗。
  • SC治疗室时间33.0-50.0分钟,IV为130.0-300.0分钟。

核心结论

  • 大多数患者强烈偏好PH FDC SC而非P+H IV。
  • PH FDC SC耐受性良好,无新安全信号,提供更快的替代方案。

主要发现

  • 136例(85.0%,95%CI 78.5-90.2%)偏好SC,22例(13.8%)偏好IV,2例(1.3%)无偏好。
  • SC偏好主要原因:减少诊所时间(n=119)和给药舒适(n=73)。
  • 86.9%选择PH FDC SC继续治疗。
  • HCP感知中位治疗室时间SC为33.0-50.0分钟,IV为130.0-300.0分钟。

关键数值与推荐

  • 大多数不良事件为1/2级,无4/5级;严重不良事件率低。
  • 切换前后不良事件率相似:IV→SC组77.5%→72.5%;SC→IV组77.5%→63.8%。

临床怎么用

  • PH FDC SC可作为HER2阳性早期乳腺癌患者偏好且耐受性良好的替代给药方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early breast cancer in PHranceSCa (NCT03674112). MATERIALS AND METHODS: Patients who completed neoadjuvant P + H + chemotherapy + surgery were randomised 1:1 to three intravenous (IV) P + H cycles followed by three cycles of PH FDC SC or vice versa (crossover) and then chose subcutaneous (SC) injection or IV infusion to continue up to 18 cycles (continuation). Assessments were via patient and healthcare professional (HCP) questionnaires. RESULTS: One hundred and sixty patients were randomised (cut-off: 24 February 2020); 136 (85.0%, 95% confidence interval: 78.5-90.2%) preferred SC; 22 (13.8%) preferred IV; 2 (1.3%) had no preference. The main reasons for SC preference were reduced clinic time (n = 119) and comfort during administration (n = 73). One hundred and forty-one patients (88.1%) were very satisfied/satisfied with SC injection versus 108 (67.5%) with IV infusion; 86.9% chose PH FDC SC continuation. HCP perceptions of median patient treatment room time ranged from 33.0-50.0 min with SC and 130.0-300.0 min with IV. Most adverse events (AEs) were grade 1/2 (no 4/5s); serious AE rates were low. AE rates before and after switching were similar (cycles 1-3 IV → cycles 4-6 SC: 77.5% → 72.5%; cycles 1-3 SC → cycles 4-6 IV: 77.5% → 63.8%). CONCLUSION: Most patients strongly preferred PH FDC SC over P + H IV. PH FDC SC was generally well tolerated, with no new safety signals (even when switching), and offers a quicker alternative to IV infusion.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. O'Shaughnessy J, Sousa S, Cruz J, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021. PMID: 34147014. doi:10.1016/j.ejca.2021.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。